Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront
罗氏与现有合作伙伴C4 Therapeutics携手涉足DACs，先期支付2000万美元

While antibody-drug conjugates have had their moment in the sun for the past few years, a degrader twist on the hot cancer modality is gathering steam.
过去几年里，抗体药物偶联物风头正劲，如今在这一炙手可热的肿瘤治疗模式上加入“降解剂”新玩法，正迅速升温。